Orthocell has received regulatory approval from Singapore’s Health Sciences Authority (HSA) for its market leading dental guided bone regeneration product, Striate+™.
This approval complements existing approvals in the US, Europe/UK, Australia, New Zealand and Canada, and paves the way for further expansion into other ASEAN markets.
BioHorizons, our global marketing and distribution partner, is already well established in Singapore, which will facilitate a fast transition to first sales in this key market.
Orthocell CEO and MD, Paul Anderson, said:
“We are delighted to receive Singaporean regulatory approval for Striate+ in this important regional gateway market. This approval provides additional validation of Orthocell’s high-quality products, manufacturing processes, and quality systems. Moreover, it enhances our ability to drive revenue growth as our distribution partner expands into global markets.”